Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Research into Cold Cancers Heating Up

Activation and expansion are essential for success in both autologous and allogeneic therapies.

Development of Gamma-Delta T-Cell Therapies

Continuous manufacturing and a quality-by-design development approach are a natural fit.

QbD for Small-Molecule Continuous Process Development

Topic

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Articles

Coprocessed excipients save time and cost while improving performance in a widening array of dosage forms.

Formulating with Coprocessed Excipients: Current Trends

Mike Hennessy Jr. is the Chairman and CEO of 

Pharma's ability to continually reinvent itself will be critical in growing future business operations.

Billions of Reasons to be Buoyant

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Videos

Extensive research on various gene editing techniques could inform the future of mRNA therapies.

Nascent Science is Likely the Future for mRNA

Twist Bioscience is a synthetic biology and genomics company that has developed a DNA synthesis platform to industrialize the engineering of biology, which is a new method of this process by “writing” DNA on a silicon chip.

Ono Pharmaceutical Enters Drug Discovery Collaboration Agreement with Twist Bioscience

Webcasts

Webinar Date/Time: Thursday, September 21, 2023 at 11am ET | 10am CT | 8am PT | 4 pm BST

A Big Impact: Trends Shaping Small-Molecule APIs, Excipients, and Formulations

Webinar Date/Time: Wed, Sep 20, 2023 11:00 AM EDT

Enteric Delivery of My API: How to Make It Right?

The formulation will be used to mitigate emerging infectious diseases and public health emergencies.

Revive Therapeutics Announces Initiation of New Bucillamine Formulation Development

Feliza Mirasol is the science editor for 

FDA has halted enrollment in clinical studies for Gilead Sciences’ magrolimab, a biologic treatment in development for acute myeloid leukemia.

FDA Halts Clinical Trial Enrollment for Gilead’s Magrolimab in AML Studies

With this agreement, Chiesi Global Rare Diseases will co-develop drug delivery systems with Aliada Therapeutics for large-molecule therapeutics that can cross the blood-brain barrier.

Chiesi Global Rare Diseases and Aliada Therapeutics Partner to Advance Blood-Brain Barrier-Crossing Platform Technology for Drug Delivery

A major grant from the Bill & Melinda Gates Foundation will bolster efforts to fight the global HIV/AIDS epidemic.

Drug Development

Research into Cold Cancers Heating Up

Development of Gamma-Delta T-Cell Therapies

QbD for Small-Molecule Continuous Process Development